Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Clarus Funds is a venture capital organization established to focus on the life sciences sector, particularly in the late-stage development of medicines and technologies. Founded as part of Blackstone Life Sciences (BXLS), the firm collaborates with pharmaceutical, biotech, and medical technology companies to address unmet medical needs. The organization aims to bring vital medicines to market by designing, funding, and executing clinical trials.
Currently, Clarus Funds manages approximately $2.6 billion in assets under management (AUM) and has invested in over 50 portfolio companies. The firm has a strong emphasis on collaboration, leveraging its position within Blackstone Life Sciences to enhance its investment strategy. Notable milestones include significant partnerships and funding initiatives that have advanced the development of innovative healthcare solutions.
Clarus Funds primarily invests in late-stage life science products and companies, specifically targeting Series C and Series D funding rounds as well as growth equity opportunities. Their investment strategy is centered on funding the development of innovative core products from credible counterparties, with a focus on generating market-unrelated returns at lower risk. The firm operates across various therapeutic areas, emphasizing collaboration with leading companies in the life sciences sector.
Clarus Funds seeks to partner with companies that are addressing significant medical needs and have the potential for substantial market impact. They prioritize investments that demonstrate a clear path to commercialization and are backed by strong scientific evidence. The firm’s approach includes a preference for deal structures that allow for shared risk and reward, fostering long-term partnerships with their portfolio companies.
Clarus Funds has made notable investments and collaborations in the life sciences sector, including:
These investments highlight Clarus Funds' commitment to advancing innovative healthcare solutions and their strategic approach to partnering with leading companies in the life sciences.
Nick Galakatos - Global Head of Blackstone Life Sciences, with extensive experience in life sciences investments and strategic collaborations.
Paris Panayiotopoulos - Role not specified, but involved in investment decisions within the firm.
Kurt Wheeler - Role not specified, contributing to the firm's investment strategy.
Barry Gertz - Role not specified, likely involved in portfolio management.
Dennis Henner - Role not specified, contributing to investment evaluations.
Deborah Dunsire - Role not specified, likely involved in strategic initiatives.
Kiran Reddy - Role not specified, contributing to investment decisions.
Olivier Brandicourt - Role not specified, likely involved in healthcare investments.
John Maraganore - Role not specified, contributing to the firm's strategic direction.
Peter Honig - Role not specified, likely involved in scientific evaluations.
Mikael Dolsten - Role not specified, contributing to life sciences investments.
Allison Jeynes-Ellis - Role not specified, likely involved in operational support.
Sean Harper - Role not specified, contributing to investment evaluations.
To pitch to Clarus Funds, founders should visit their website at Clarus Funds for guidance on the application process. A well-structured pitch deck should include details about the product, market analysis, development timelines, and the team’s expertise. Specific response time expectations are not provided, and warm introductions may enhance the chances of a successful pitch.
In March 2024, Clarus Funds announced a collaboration with Moderna to advance an influenza mRNA vaccine program, providing up to $750 million in funding. This partnership highlights the firm's active involvement in significant life sciences initiatives.
In April 2020, Clarus Funds led a $2 billion strategic collaboration with Alnylam Pharmaceuticals, acquiring a royalty interest in inclisiran (Leqvio®), a product aimed at treating high cholesterol. This investment underscores the firm's commitment to funding innovative healthcare solutions.
Additionally, Anthos Therapeutics, Inc., founded in February 2019 in collaboration with Novartis, was sold to Novartis in April 2025, marking a notable exit for Clarus Funds and demonstrating their successful investment strategy in the life sciences sector.
What are Clarus Funds' investment criteria?
Clarus Funds primarily invests in late-stage life science products and companies, focusing on Series C and Series D funding rounds as well as growth equity opportunities. They look for innovative core products from credible counterparties that address significant medical needs.
How can I apply or pitch to Clarus Funds?
Founders interested in pitching to Clarus Funds can visit their website at Clarus Funds for more information on the application process. Specific email addresses for pitches are not provided.
What makes Clarus Funds different from other venture capital firms?
Clarus Funds differentiates itself through its affiliation with Blackstone Life Sciences, which provides extensive resources and expertise in funding and executing clinical trials. Their focus on generating market-unrelated returns at lower risk also sets them apart.
What is the geographic scope of Clarus Funds' investments?
Clarus Funds primarily focuses on investments within the life sciences sector, which includes biotech and healthcare companies, although specific geographic preferences are not detailed.
What is the typical check size for investments?
While specific check sizes are not disclosed, Clarus Funds engages in significant funding rounds, as evidenced by their $750 million collaboration with Moderna and $2 billion partnership with Alnylam Pharmaceuticals.
What type of post-investment involvement does Clarus Funds have?
Clarus Funds emphasizes collaboration with their portfolio companies, providing support in the development and execution of clinical trials, which is crucial for the success of life sciences ventures.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.